APOC3 and pancreatitis: Volanesorsen (Waylivra), an earlier ApoC-III-targeted antisense oligonucleotide, received conditional approval in the European Union in May 2019 for adults with genetically confirmed FCS who were at high risk of pancreatitis [15].